Beta Bionics, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
BBNX$16.52-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
The information required by this item will be set forth in our Proxy Statement, under the section headed “Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm,” and is incorporated herein by reference.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
|---|---|
| Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Statements of Operations and Comprehensive Loss for the Years ended December 31, 2025 and 2024 | F-4 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2025 and 2024 | F-5 |
| Statements of Cash Flows for the Years ended December 31, 2025 and 2024 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.